The relationship between inflammatory bowel diseases and kidney diseases

Abstract

Inflammatory bowel diseases occupy a significant place among all diseases of the gastrointestinal tract. According to D. Corica, the prevalence of extra-intestinal manifestations in inflammatory bowel diseases ranges from 6 % to 46 %. Gastroenterologists are well aware of local intestinal manifestations of these diseases. The etiology of extra-intestinal manifestations is still unclear. However, it is well known that these injuries are not limited to the intestines and one of the target organs is the kidneys. The following review presents the analysis of possible pathogenetic mechanisms of intestinal and kidney lesions, such as Crohn’s disease, ulcerative colitis and urolithiasis, tubulointerstitial nephritis, glomerulonephritis and amyloidosis of the kidneys.

Keywords

kidneys / intestines / inflammation / diseases / Crohn’s disease / ulcerative colitis / urolithiasis / tubulointerstitial nephritis / glomerulonephritis / amyloidosis

References

[1] Corica D, Romano C. Renal involvement in inflammatory bowel diseases. J Crohns Colitis. 2016;10(2):226–235. DOI: 10.1093/ecco-jcc/jjv138

[2] Corica D., Romano C. Renal involvement in inflammatory bowel diseases // J. Crohns. Colitis. 2016. Vol. 10, No. 2. P. 226–235. DOI: 10.1093/ecco-jcc/jjv138

[3] Bel’mer SV, Gasilina TV. Systems of the organs of digestion and organs of the elimination of urine: the morpho-functional and clinical generality [Internet]. Lechashhij vrach. 2013:6–20. Available from: https://www.lvrach.ru/2013/06/15435723. Accessed: Mar 12, 2022. (In Russ.)

[4] Бельмер С.В., Гасилина Т.В. Системы органов пищеварения и органов мочевыделения: морфофункциональная и клиническая общность [Электронный ресурс] // Лечащий врач. 2013. С. 6–20. Режим доступа: https://www.lvrach.ru/2013/06/15435723. Дата обращения: 12.03.2022.

[5] Monteiro RC, Berthelo L. Role of gut-kidney axis in renal diseases and IgA nephropathy. Curr Opin Gastroenterol. 2021;37(6):565–571. DOI: 10.1097/MOG.0000000000000789

[6] Monteiro R.C., Berthelo L. Role of gut-kidney axis in renal diseases and IgA nephropathy // Curr. Opin. Gastroenterol. 2021. Vol. 37, No. 6. P. 565–571. DOI: 10.1097/MOG.0000000000000789

[7] Chen YY, Chen DQ, Chen L, et al. Microbiome-metabolome reveals the contribution of gut-kidney axis on kidney disease. J Transl Med. 2019;17(1):5. DOI: 10.1186/s12967-018-1756-4

[8] Chen Y.Y., Chen D.Q., Chen L. et al. Microbiome-metabolome reveals the contribution of gut-kidney axis on kidney disease // J. Transl. Med. 2019. Vol. 17, No. 1. P. 5. DOI: 10.1186/s12967-018-1756-4

[9] Helvaci MR, Algin MC, Kaya H. Irritable bowel syndrome and chronic gastritis, hemorrhoid, urolithiasis. Eurasian J Med. 2009;41(3):158–161.

[10] Helvaci M.R., Algin M.C., Kaya H. Irritable bowel syndrome and chronic gastritis, hemorrhoid, urolithiasis // Eurasian J. Med. 2009. Vol. 41, No. 3. P. 158–161.

[11] Prives MG, Lysenkov NK, Bushkovich VI. Human anatomy: textbook. Saint Petersburg; 2009. P. 266–267. (In Russ.)

[12] Привес М.Г., Лысенков Н.К., Бушкович В.И. Анатомия человека: учебник. СПб.: СПбМАПО, 2009. С. 266–267.

[13] Takemura T, Okada M, Yagi K, et al. An adolescent with IgA nephropathy and Crohn disease: pathogenetic implications. Pediatr Nephrol. 2002;17(10):863–866. DOI: 10.1007/s00467-002-0943-x

[14] Takemura T., Okada M., Yagi K. et al. An adolescent with IgA nephropathy and Crohn disease: pathogenetic implications // Pediatr. Nephrol. 2002. Vol. 17, No. 10. P. 863–866. DOI: 10.1007/s00467-002-0943-x

[15] Lakatos L, Pandur T, David G, et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol. 2003;9(10):2300–2307. DOI: 10.3748/wjg.v9.i10.2300

[16] Lakatos L., Pandur T., David G. et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study // World J. Gastroenterol. 2003. Vol. 9, No. 10. P. 2300–2307. DOI: 10.3748/wjg. v9.i10.2300

[17] Ambruzs JM, Walker PD, Larsen CP. The hystopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease. Clin J Am Soc Nephrol. 2014;9(2):265–270. DOI: 10.2215/CJN.04660513

[18] Ambruzs J.M., Walker P.D., Larsen C.P. The hystopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease // Clin. J. Am. Soc. Nephrol. 2014. Vol. 9, No. 2. P. 265–270. DOI: 10.2215/CJN.04660513

[19] Pouria S, Barratt J. Secondary IgA nephropathy. Semin Nephrol. 2008;28(1):27–37. DOI: 10.1016/j.semnephrol.2007.10.004

[20] Pouria S., Barratt J. Secondary IgA nephropathy // Semin. Nephrol. 2008. Vol. 28, No. 1. P. 27–37. DOI: 10.1016/j.semnephrol.2007.10.004

[21] Kiryluk K, Li Y, Scolari F, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014;46(11):1187–1196. DOI: 10.1038/ng.3118

[22] Kiryluk K., Li Y., Scolari F. et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens // Nat. Genet. 2014. Vol. 46, No. 11. P. 1187–1196. DOI: 10.1038/ng.3118

[23] Warling O, Bovy C, Coimbra C, et al. Overlap syndrome consisting of PSC-AIH with concomitant presence of a membranous glomerulonephritis and ulcerative colitis. World J Gastroenterol. 2014;20(16):4811–4816. DOI: 10.3748/wjg.v20.i16.4811

[24] Warling O., Bovy C., Coimbra C. et al. Overlap syndrome consisting of PSC-AIH with concomitant presence of a membranous glomerulonephritis and ulcerative colitis // World J. Gastroenterol. 2014. Vol. 20, No. 16. P. 4811–4816. DOI: 10.3748/wjg.v20.i16.4811

[25] Wilcox GM, Aretz HT, Roy MA, Roche JK. Glomerulonephritis associated with inflammatory bowel disease. Report of a patient with chronic ulcerative colitis, sclerosing cholangitis, and acute glomerulonephritis. Gastroenterology. 1990;98(3):786–791.

[26] Wilcox G.M., Aretz H.T., Roy M.A., Roche J.K. Glomerulonephritis associated with inflammatory bowel disease. Report of a patient with chronic ulcerative colitis, sclerosing cholangitis, and acute glomerulonephritis // Gastroenterology. 1990. Vol. 98, No. 3. P. 786–791.

[27] Herrlinger KR, Noftz MK, Fellermann K, et al. Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use. Aliment Pharmacol Ther. 2001;15(3):363–369. DOI: 10.1046/j.1365-2036.2001.00940.x

[28] Herrlinger K.R., Noftz M.K., Fellermann K. et al. Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use // Aliment. Pharmacol. Ther. 2001. Vol. 15, No. 3. P. 363–369. DOI: 10.1046/j.1365-2036.2001.00940.x

[29] Poulou AC, Goumas KE, Dandakis DC, et al. Microproteinuria in patients with inflammatory bowel disease: is it associated with the disease activity or the treatment with 5-aminosalicylic acid? World J Gastroenterol. 2006;12(5):739–746. DOI: 10.3748/wjg.v12.i5.739

[30] Poulou A.C., Goumas K.E., Dandakis D.C. et al. Microproteinuria in patients with inflammatory bowel disease: is it associated with the disease activity or the treatment with 5-aminosalicylic acid? // World J. Gastroenterol. 2006. Vol. 12, No. 5. P. 739–746. DOI: 10.3748/wjg.v12.i5.739

[31] Fraser JS, Muller AF, Smith DJ, et al. Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy. Aliment Pharmacol Ther. 2001;15(8):1131–1137. DOI: 10.1046/j.1365-2036.2001.01041.x

[32] Fraser J.S., Muller A.F., Smith D.J. et al. Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy // Aliment. Pharmacol. Ther. 2001. Vol. 15, No. 8. P. 1131–1137. DOI: 10.1046/j.1365-2036.2001.01041.x

[33] Tokuyama H, Wakino S, Konishi K, et al. Acute interstitial nephritis associated with ulcerative colitis. Clin Exp Nephrol. 2010;14(5):483–486. DOI: 10.1007/s10157-010-0294-z

[34] Tokuyama H., Wakino S., Konishi K. et al. Acute interstitial nephritis associated with ulcerative colitis // Clin. Exp. Nephrol. 2010. Vol. 14, No. 5. P. 483–486. DOI: 10.1007/s10157-010-0294-z

[35] Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51(4):536–539. DOI: 10.1136/gut.51.4.536

[36] Ransford R.A., Langman M.J. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines // Gut. 2002. Vol. 51, No. 4. P. 536–539. DOI: 10.1136/gut.51.4.536

[37] Shilov EM, Batyushin MM. Clinical recommendations for the diagnosis and treatment of chronic tubulointerstitial nephritis 2015 [Internet]. Available from: http://nonr.ru/wp-content/uploads/2013/11/Клинические-рекомендации-по-диагностике-и-лечению-хронического-тубулоинтерстициального-нефрита1.pdf. Accessed: Mar 12, 2022. (In Russ.)

[38] Шилов Е.М., Батюшин М.М. Клинические рекомендации по диагностике и лечению хронического тубулоинтерстициального нефрита 2015 [Электронный ресурс]. Режим доступа: http://nonr.ru/wp-content/uploads/2013/11/Клинические-рекомендации-по-диагностике-и-лечению-хронического-тубулоинтерстициального-нефрита1.pdf. Дата обращения: 12.03.2022.

[39] Wester AL, Vatn MH, Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis. 2001;7(4):295–300. DOI: 10.1097/00054725-200111000-00003

[40] Wester A.L., Vatn M.H., Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998 // Inflamm. Bowel Dis. 2001. Vol. 7, No. 4. P. 295–300. DOI: 10.1097/00054725-200111000-00003

[41] Parks JH, Worcester EM, O’Connor RC, Coe FL. Urine stone risk factors in nephrolithiasis patients with and without bowel disease. Kidney Int. 2003;63(1):255–265. DOI: 10.1046/j.1523-1755.2003.00725.x

[42] Parks J.H., Worcester E.M., O’Connor R.C., Coe F.L. Urine stone risk factors in nephrolithiasis patients with and without bowel disease // Kidney Int. 2003. Vol. 63, No. 1. P. 255–265. DOI: 10.1046/j.1523-1755.2003.00725.x

[43] McConnell N, Campbell S, Gillanders I, et al. Risk factors for developing renal stones in inflammatory bowel disease. BJU Int. 2002;89(9):835–841. DOI: 10.1046/j.1464-410x.2002.02739.x

[44] McConnell N., Campbell S., Gillanders I. et al. Risk factors for developing renal stones in inflammatory bowel disease // BJU Int. 2002. Vol. 89, No. 9. P. 835–841. DOI: 10.1046/j.1464-410x.2002.02739.x

[45] Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006;12(30):4819–4831. DOI: 10.3748/wjg.v12.i30.4819

[46] Rothfuss K.S., Stange E.F., Herrlinger K.R. Extraintestinal manifestations and complications in inflammatory bowel diseases // World J. Gastroenterol. 2006. Vol. 12, No. 30. P. 4819–4831. DOI: 10.3748/wjg.v12.i30.4819

[47] Dorofeev AJe, Rudenko NN, Derkach IA, Chechula JuV. Bowel diseases and kidneys. Look around that lecture. Journal of Gastroenterology of Ukraine. 2915;3(57):101–105. Available from: https://cyberleninka.ru/article/n/zabolevaniya-kishechnika-i-pochki. Accessed: Mar 12, 2022. (In Russ.)

[48] Дорофеев А.Э., Руденко Н.Н., Деркач И.А., Чечула Ю.В. Заболевания кишечника и почки // Журнал гастроэнтерологии Украины. 2015. № 3(57). С. 101–105. [Электронный ресурс]. Режим доступа: https://cyberleninka.ru/article/n/zabolevaniya-kishechnika-i-pochki. Дата обращения: 12.03.2022.

[49] Chou YH, Huang CN, Li WM, et al. Clinical study of ammonium acid urate urolithiasis. Kaohsiung J Med Sci. 2012;28(5):259–264. DOI: 10.1016/j.kjms.2011.11.004

[50] Chou Y.H., Huang C.N., Li W.M. et al. Clinical study of ammonium acid urate urolithiasis // Kaohsiung J. Med. Sci. 2012. Vol. 28, No. 5. P. 259–264. DOI: 10.1016/j.kjms.2011.11.004

[51] Ishii G, Nakajima K, Tanaka N, et al. Clinical evaluation of urolithiasis in Crohn’s disease. Int J Urol. 2009;16(5):477–480. DOI: 10.1111/j.1442-2042.2009.02285.x

[52] Ishii G., Nakajima K., Tanaka N. et al. Clinical evaluation of urolithiasis in Crohn’s disease // Int. J. Urol. 2009. Vol. 16, No. 5. P. 477–480. DOI: 10.1111/j.1442-2042.2009.02285.x

[53] Sakhaee K. Epidemiology and clinical pathophysiology of uric acid kidney stones. J Nephrol. 2014;27(3):241–245. DOI: 10.1007/s40620-013-0034-z

[54] Sakhaee K. Epidemiology and clinical pathophysiology of uric acid kidney stones // J. Nephrol. 2014. Vol. 27, No. 3. P. 241–245. DOI: 10.1007/s40620-013-0034-z

RIGHTS & PERMISSIONS

Barysheva O.Y., Simanov R.N.